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ABSTRACT: Characterization of amyloid β (Aβ) oligomers, the transition
species present prior to the formation of Aβ fibrils and that have
cytotoxicity, has become one of the major topics in the investigations of
Alzheimer’s disease (AD) pathogenesis. However, studying pathophysio-
logical properties of Aβ oligomers is challenging due to the instability of
these protein complexes in vitro. Here, we report that conformation-
restricted Aβ42 with an intramolecular disulfide bond at positions 17 and
28 (SS-Aβ42) formed stable Aβ oligomers in vitro. Thioflavin T binding
assays, nondenaturing gel electrophoresis, and morphological analyses
revealed that SS-Aβ42 maintained oligomeric structure, whereas wild-type Aβ42 and the highly aggregative Aβ42 mutant with E22P
substitution (E22P-Aβ42) formed Aβ fibrils. In agreement with these observations, SS-Aβ42 was more cytotoxic compared to the
wild-type and E22P-Aβ42 in cell cultures. Furthermore, we developed a monoclonal antibody, designated TxCo-1, using the toxic
conformation of SS-Aβ42 as immunogen. X-ray crystallography of the TxCo-1/SS-Aβ42 complex, enzyme immunoassay, and
immunohistochemical studies confirmed the recognition site and specificity of TxCo-1 to SS-Aβ42. Immunohistochemistry with
TxCo-1 antibody identified structures resembling senile plaques and vascular Aβ in brain samples of AD subjects. However, TxCo-1
immunoreactivity did not colocalize extensively with Aβ plaques identified with conventional Aβ antibodies. Together, these findings
indicate that Aβ with a turn at positions 22 and 23, which is prone to form Aβ oligomers, could show strong cytotoxicity and
accumulated in brains of AD subjects. The SS-Aβ42 and TxCo-1 antibody should facilitate understanding of the pathological role of
Aβ with toxic conformation in AD.
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■ INTRODUCTION
Amyloid β (Aβ) plays a critical role in the pathogenesis of
Alzheimer’s disease (AD).1,2 Aberrant accumulation of Aβ
leads to formation of Aβ plaques and subsequent neuro-
degeneration.3 Aβ plaques consist of highly ordered fibrillar
aggregates of Aβ. The formation of Aβ fibrils takes several
steps: oligomerization of monomeric Aβ, formation of
protofibrils from Aβ oligomers, and aggregation into Aβ
fibrils.4,5 Studies have shown that Aβ oligomers, an
intermediate transition form of Aβ, have more neurotoxic
effects compared with Aβ fibrils.6−8 Many factors could
influence formation of toxic Aβ oligomers. Cellular membranes
appear to play an important role in promoting formation of Aβ
ol igomers . 9 Aβ fibr i l s can bind to monos ia lo -
tetrahexosylganglioside (GM1) in rafts with various mem-
brane-bound conformations that cause membrane disrup-
tion.10−12 Metal ions like copper and zinc are also involved in
the aggregation process of Aβ.9 Although Aβ42 is more
neurotoxic than Aβ40 as a single alloform, the interplay
between these Aβ species might also be important in AD
pathology.13 Computer simulations predicted the structure of
disordered Aβ in solution.14 Further detailed studies of Aβ
oligomers are warranted, yet are challenging due to the
instability of these protein complexes in vitro.
Cross-linkage of Aβ is one strategy to investigate Aβ
oligomers.15−17 The tertiary structure of Aβ oligomers can be
fixed either by inducing cross-linking of the proteins with
amino acid substitutions or by using a cross-linking reagent.
Formation of an intramolecular bond is a different strategy to
stabilize Aβ oligomers.18 Sandberg et al. generated Aβ42 with
an intramolecular disulfide bond at positions 21 and 30 (Aβcc)
and showed that it formed stable oligomers and was resistant
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Figure 1. Features of fibrillization of WT-Aβ42, E22P-Aβ42, SS-Aβ42 in PBS. (A) Fibrillization of Aβ peptides in PBS was assessed by Th-T
binding assay. Fluorescence fold change indicates that E22P-Aβ42 and WT-Aβ42 showed high trend of Aβ fibrillization, followed by SS-Aβ42.
Values are average ± SD (n = 3). (B) The size and nature of Aβ aggregates were assessed by nondenaturing PAGE. WT-Aβ42 and E22P-Aβ42
showed protein bands at the size over 1000 kDa, while SS-Aβ42 exhibited a variable smear. (C) WT-Aβ42, E22P-Aβ42, and SS-Aβ42 were cross-
linked using PICUP. The 0 min samples were subjected to PICUP immediately after being dissolved in phosphate buffer. The 5 min samples were
incubated at 37 °C for 5 min prior to PICUP. The samples were analyzed by tricine−SDS/PAGE and visualized by silver staining. The band
patterns of WT-Aβ42 and SS-Aβ42 showed little difference, whereas a 5 min incubation promoted the rapid Aβ oligomerization of E22P-Aβ42. (D)
Morphology of Aβ aggregates formed in PBS and attached on cover glass was observed by confocal microscopy. Top row shows representative
images taken by ×63 objective lens, and bottom row shows images taken by ×63 objective lens with ×3 zoom. WT-Aβ42 and E22P-Aβ42 became
fibrils in size over 20 μm. Thread-like Aβ appeared all over the field in E22P-Aβ42. Countless bead-like structures attached on the surface of cover
glass with SS-Aβ42. Scale bar, 20 μm in top row and 5 μm in bottom row. (E) Morphology of the protein complexes of SS-Aβ42 formed in PBS
was observed by atomic force microscopy. Left panel shows the morphology of SS-Aβ42 prior to the incubation, and right panel shows its
morphology after 24 h incubation. Size, around 50 nm, and morphology of SS-Aβ42 were uniform prior to the incubation. After the incubation,
some of the SS-Aβ42 extended their size up to 400 nm, and others remained the same size. Scale bar, 200 nm. Data information: Significance was
calculated using one-way ANOVA with post hoc Tukey: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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to forming fibrils. This study suggested that the conformational
locking of monomeric Aβ partially inhibits the formation of
intermolecular hydrogen bonds between β-strands of Aβ,
thereby stabilizing Aβ complexes as oligomers.
Analysis of aggregates of Aβ42 with systematic proline
replacement followed by solid-state nuclear magnetic reso-
nance (NMR) revealed that Aβ42 adopts two conformations:
one with a turn at positions 22 and 23, another with a turn at
positions 25 and 26.19−22 These studies revealed that Aβ42
with a turn at positions 22 and 23 was highly aggregative and
neurotoxic.23 For intrinsically disordered proteins like Aβ,
structural perturbation by chiral inversion of the focused amino
acid residue (chiral editing) could be valuable to investigate
their conformational change.24 Substitution of L-Glu with D-
Glu at position 22 of Aβ42 attenuated propensity to form
fibrils and enhanced cytotoxicity against PC12 cells.25 Age-
related epimerization at Ser26 reduced the toxicity of Aβ42 by
stabilization of the aggregation intermediates.26 Systematic
chiral mutation at the central region of Aβ42 revealed that D-
amino acid replacement at Glu22 makes Aβ42 more soluble
and more neurotoxic, while that at Ser26 makes Aβ42 even
more soluble but non-neurotoxic.27,28 These data are in
agreement with our hypothesis of the existence of a toxic
conformer with a turn at positions 22 and 23 and that of the
less toxic conformer with a turn at positions 25 and 26.22,23
Matsushima et al. developed a conformation-restricted Aβ42
with an intramolecular disulfide bond at positions 17 and 28
(SS-Aβ42) to stabilize the toxic turn at positions 22 and 23
without proline replacement.29 This synthetic form of Aβ42
displayed stronger neurotoxicity against SH-SY5Y cells and
more resistance to the formation of Aβ fibrils compared to the
wild-type Aβ42 (WT-Aβ42). This is the first example of
conformation-restricted toxic Aβ42 with wild-type sequence
from position 19 to position 26. This result could be due to the
stabilization of Aβ oligomers by conformational lock at
positions 17 and 28 via disulfide bond which consecutively
could stabilize the toxic turn at positions 22 and 23 and
inhibits partially the formation of intermolecular parallel β-
strands of Aβ42, a crucial stage in Aβ fibrillization.
The purpose of this study was to further investigate SS-Aβ42
in the context of Aβ fibrillization and cytotoxicity compared to
WT-Aβ42 and the highly aggregative Aβ42 mutant with E22P
substitution (E22P-Aβ42), thereby to establish it as a tool to
study Aβ oligomers in vitro. Furthermore, we generated a
monoclonal antibody, designated TxCo-1, using SS-Aβ42 as
immunogen to study toxic Aβ oligomers in brain tissue. Since
SS-Aβ42 retains native peptide sequence from position 19 to
position 26, the antibody TxCo-1 targeting the toxic turn could
be an ideal tool to study the presence of toxic forms of Aβ in
brain tissue.
■ RESULTS AND DISCUSSION
Fibrillization of Aβ Peptides in PBS. Features of
fibrillization of Aβ peptides in PBS were assessed by thioflavin
T (Th-T) binding assay, nondenaturing PAGE, and morpho-
logical analysis. 4 μM WT-Aβ42, E22P-Aβ42, and SS-Aβ42
peptides were incubated in PBS for 24 h at 37 °C. The samples
were mixed with Th-T, adjusting its concentration at 20 μM,
and then further incubated for 12 h at 24 °C. Then,
fluorescence intensity was measured (Figure 1A). On the
basis of the fluorescence fold changes, WT-Aβ42 and E22P-
Aβ42 showed the highest trend of Aβ fibrillization, followed by
SS-Aβ42. Next, we confirmed the molecular size of Aβ
aggregates formed in PBS. 0.25, 0.5, and 1.0 μM WT-Aβ42,
E22P-Aβ42, and SS-Aβ42 peptides were incubated in PBS for
24 h at 37 °C, and the size of Aβ aggregates was assessed under
nondenaturing conditions by blue-native gel electrophoresis
(Figure 1B). A single band of over 1000 kDa appeared at the
top of the lanes in WT-Aβ42 and E22P-Aβ42, and the signal
intensity increased with increasing concentrations of the Aβ
peptides. In contrast, SS-Aβ42 showed smears ranging roughly
from 50 to 1000 kDa, and the signal intensity increased with
increasing concentration of the Aβ peptide. These data
indicate that WT-Aβ42 and E22P-Aβ42 become aggregates
with sizes over 1000 kDa in PBS, while SS-Aβ42 formed
different types of aggregates of various sizes less than 700 kDa
(150-mer). Next, in order to assess the rate of Aβ aggregation,
we prepared Aβ oligomers and stabilized the structure by
cross-linking with photo-induced cross-linking of unmodified
proteins (PICUP).15 PICUP is a method that enables
formation of covalent bonds between closely interacting
polypeptides such as Aβ oligomers to monitor the formation
of the protein complexes. 50 μM WT-Aβ42, E22P-Aβ42, and
SS-Aβ42 peptides were used immediately in PICUP assay (0
min) after being dissolved in phosphate buffer or were
incubated at 37 °C for 5 min prior to the experiment. The
band patterns of WT-Aβ42 and SS-Aβ42 showed little
difference, whereas a 5 min incubation promoted the rapid
Aβ oligomerization of E22P-Aβ42. These data suggest that the
rate of Aβ42 oligomerization is faster in E22P-Aβ42. Lastly, we
observed the morphology of Aβ aggregates formed in PBS. 1.0
μM WT-Aβ42, E22P-Aβ42, SS-Aβ42 peptides were incubated
in PBS for 24 h at 37 °C and observed by confocal microscopy
(Figure 1D). WT-Aβ42 and E22P-Aβ42 peptides formed
structures resembling typical Aβ fibrils with sizes over 20 μm.
In E22P-Aβ42, rope and bead-like Aβ appeared uniformly in
the observed fields. In contrast, large Aβ aggregates were not
observed in SS-Aβ42, and numerous fine thread and bead-like
structures smaller than those observed in E22P-Aβ42 appeared
uniformly in the observed field. Since the morphology of
aggregates formed by SS-Aβ42 was not well-defined by
confocal microscopy, we examined it in further detail by
atomic force microscopy (AFM) (Figure 1E). SS-Aβ42
displayed uniform shape and size prior to the incubation.
With 24 h incubation, some SS-Aβ42 formed aggregates. On
the basis of results of low Th-T binding and gel migration
pattern, we suggest that SS-Aβ42 does not form structures
resembling typical Aβ fibrils in PBS and remains as oligomers
of various sizes.
The degree of Aβ oligomerization/fibrillization of SS-Aβ42
was monitored by Th-T binding assay, nondenaturing PAGE,
PICUP, and morphological analyses comparing the results with
those of WT-Aβ42 and E22P-Aβ42. We found that SS-Aβ42
did not form the large fibrils observed in WT-Aβ42 and E22P-
Aβ42 and remained as small particles resembling protofibril in
PBS. The result of PICUP experiment suggests that E22P-
Aβ42 has a faster rate of oligomerization. However, caution
should be made in the interpretation of the PICUP data. In our
hands, identification of oligomers higher than heptamers might
be difficult to detect by PICUP.15,30 However, Aβ42 aggregates
of higher molecular weight were observed using nondenaturing
PAGE. The results of PICUP and nondenaturing PAGE
indicate that SS-Aβ42 does not form the Aβ fibrils observed in
WT-Aβ42 and E22P-Aβ42.
Fibrillization of Aβ Peptides in Cell Culture Media. To
investigate fibrillization of Aβ peptides in solution with
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complex biological constituents, we conducted Th-T binding
assays, nondenaturing PAGE, and morphological analysis on
Aβ peptides incubated in 1% FBS/RPMI1640 culture media. 4
μM WT-Aβ42, E22P-Aβ42, and SS-Aβ42 peptides were
incubated in 1% FBS/RPMI1640 for 24 h at 37 °C. The
samples were mixed with Th-T, adjusting its concentration to
20 μM, and further incubated for 12 h at 24 °C. Then,
fluorescence intensity was measured (Figure 2A). On the basis
of the fluorescence fold changes, E22P-Aβ42 showed the high
trend of Aβ fibrillization compared to WT-Aβ42 and SS-Aβ42.
Next, we assessed the size of Aβ oligomers formed in 1% FBS/
RPMI1640. 0.25, 0.5, and 1.0 μM WT-Aβ42, E22P-Aβ42, SS-
Aβ42 peptides were incubated in 1% FBS/RPMI1640 for 24 h
at 37 °C, and the size of aggregates was assessed under
nondenaturing conditions by blue-native gel electrophoresis
(Figure 2B). For WT-Aβ42 and E22P-Aβ42, a single band over
1000 kDa appeared at the top of the lane together with smears
ranging from roughly 200 to over 1000 kDa. The signal
intensity increased with concentration of these Aβ peptides. In
the lane loaded with E22P-Aβ42 at 1.0 μM, a band appeared
below the molecular marker at 66 kDa. In contrast, SS-Aβ42
showed a smear ranging roughly from 50 to over 1000 kDa.
Lastly, we observed morphology of Aβ aggregates formed in
1%FBS/RPMI1640. 1.0 μM WT-Aβ42, E22P-Aβ42, SS-Aβ42
peptides were incubated in 1% FBS/RPMI1640 for 24 h at 37
°C and observed by confocal microscopy (Figure 2C). WT-
Aβ42 and E22P-Aβ42 peptides formed a structure resembling
Aβ fibrils/aggregates, yet its size was reduced to 10 μm or less.
Rope-like Aβ aggregates appeared uniformly in E22P-Aβ42. In
SS-Aβ42, noticeable Aβ signal could not be detected in the
observed field. These results show the same trends as
aggregation occurring in PBS, but the protein present in 1%
FBS has significantly slowed down the complete aggregation of
WT-Aβ42 and E22P-Aβ42.
The amount of Aβ fibrillization diminished in culture media
with complex constituents. Plasma proteins, especially serum
albumin, can be potent inhibitors of Aβ fibrillization.31,32 The
difference in results obtained with PBS and 1% FBS/RPMI
media implies that Aβ polymerization is affected by the
composition of the solution. Clearance of Aβ from brain
parenchyma can be by multiple pathways, i.e., protein
degradation, CSF, and bloodstream.33,34 A future study
correlating type of solvents and structure of Aβ complexes in
vivo could help to understand the physiology of Aβ clearance.
Toxicity, Cellular Localization, and Uptake Dynamics
of Aβ Peptides. A previous study confirmed higher
neurotoxicity of E22P-Aβ42 and SS-Aβ42 compared to the
WT-Aβ42 using the human neuroblastoma SH-SY5 cell line,29
which is generally used as a model of neurons.27,28 In the
present study, we employed THP-1 macrophage-like cells to
further explore the toxicity of these Aβ peptides. THP-1 is a
human leukemia cell line, which has many properties of native
monocyte-derived macrophage upon differentiation with
phorbol ester.35 It is an established cellular model of microglia
for studying responses to Aβ properties.36 Studies suggest
microglia are major players in neuroinflammation for the
pathogenesis of AD.37,38 Differentiated THP-1 cells were
incubated with WT-Aβ42, E22P-Aβ42, and SS-Aβ42 peptides
Figure 2. Features of fibrillization of WT-Aβ42, E22P-Aβ42, SS-Aβ42 in cell culture media. (A) Fibrillization of Aβ peptides in 1% FBS/RPMI1640
was assessed by Th-T binding assay. E22P-Aβ42 showed high trend of Aβ fibrillization compared to WT-Aβ42 and SS-Aβ42. Values are average ±
SD (n = 3). (B) The size of Aβ aggregates was assessed by nondenaturing PAGE. WT-Aβ42 and E22P-Aβ42 showed both protein bands at the size
over 1000 kDa and smear ranging from 200 to over 1000 kDa, while SS-Aβ42 exhibited smear. (C) Morphology of Aβ aggregates formed in 1%
FBS/RPMI1640 and attached on the cover glass was observed by confocal microscopy. Top row shows representative images taken by ×63
objective lens, and bottom row show images taken by ×63 objective lens with ×3 zoom. Size of fibril in WT-Aβ42 reduced to 1−5 μm. Size of fibril
in E22P-Aβ42 reduced to <10 μm, while thread-like Aβ remained similar. Noticeable Aβ was not observed in SS-Aβ42 suggesting it remained in
soluble form. Scale bar, 20 μm in top row and 5 μm in bottom row. Data information: Significance was calculated using one-way ANOVA with post
hoc Tukey: **P < 0.01, ****P < 0.0001.
ACS Chemical Neuroscience pubs.acs.org/chemneuro Research Article
https://doi.org/10.1021/acschemneuro.1c00416
ACS Chem. Neurosci. 2021, 12, 3418−3432
3421
at various concentrations in 1% FBS/RPMI1640 for 24 h at 37
°C, and cell viability was measured by MTT assay (Figure 3A).
SS-Aβ42 showed cytotoxicity at quite low concentrations even
at 25 nM, whereas WT-Aβ42 and E22P-Aβ42 exhibited a
weaker effect though E22P-Aβ42 was more potent than WT-
Aβ42 as previously reported in PC12 cells.19,39 Next, we
assessed the localization of these Aβ peptides in THP-1 cells
upon treatment as a measure of cellular uptake and processing
of these peptides. These Aβ peptides in THP-1 cells showed
three different localization patterns: puncta, aggregate, and
diffuse (Figure 3B). The THP1 cells in category puncta
exhibited multiple dots of less than 1 μm. The size of 6E10
Figure 3. Toxicity, cellular localization, and uptake dynamics of Aβ peptides with THP1 cells. (A) Cytotoxicity of WT-Aβ42, E22P-Aβ42, and SS-
Aβ42 was assessed by MTT assay. Values are average ± SD (n = 3 experiments). Statistical comparisons are indicated in blue for WT-Aβ42 and SS-
Aβ42, red for E22P-Aβ42 and SS-Aβ42, and black for WT-Aβ42 and E22P-Aβ42. (B) Patterns of Aβ localization in THP1 cells. The representative
images were taken with 63× objective lens. Scale bar, 20 μm. (C) Percentage of THP1 cells that showed localization pattern in puncta and
aggregate category. Values are average ± SD (n = 3 experiments). (D) Percentage of THP1 cells treated with SS-Aβ42 and that showed localization
pattern in diffuse category. Values are average ± SD (n = 3 experiments). (E) Colocalization of Aβ peptides with lysosome in THP1 cell upon
treatment with bafilomycin A1. The representative images were taken with 63× objective lens. Scale bar, 20 μm. (F) Percentage of THP1 cells
treated with bafilomycin A1 and that showed colocalization of 6E10 signal in lysosome. Values are average ± SD (n = 3 experiments). Data
information: Significance was calculated using one-way ANOVA with post hoc Tukey in (A) and (D) and two-way ANOVA with post hoc Tukey
in (C) and (F): *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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signals in category aggregate was over 3 μm. In the diffuse
pattern, the 6E10 signal was observed throughout the cell
body. We quantified the fraction of THP1 cells that showed
either puncta, aggregate, or both (Figure 3C). The fraction of
THP1 cells in these categories increased in both WT-Aβ42 and
E22P-Aβ42 as the concentration of these peptides increased,
and E22P-Aβ42 showed more drastic change. In contrast, only
around 1% of the cells exhibited these patterns upon SS-Aβ42
treatment. Rather, localization of SS-Aβ42 took a diffuse
pattern, which was not evident in the cells treated with WT-
Aβ42 and E22P-Aβ42. Over 80% of THP1 cells treated with
SS-Aβ42 showed a diffuse pattern at 0.5 and 1.0 μM (Figure
3D). These data indicated that these Aβ peptides show
different localization patterns in THP1 cells, while WT-Aβ42
and E22P-Aβ42 show similar patterns upon treatment. To test
whether accumulation of these Aβ peptides and different
localization patterns were due to the result of Aβ incorporation
into the cells or attachment of these peptides to the surface of
the cell membrane, we examined the accumulation of these Aβ
peptides in the presence of bafilomycin A1, an inhibitor of
lysosomal H+-ATPases that blocks lysosomal degradation.40
We found that these Aβ peptides colocalized with lysosomal
marker CD68 (Figure 3E). Next, we quantified the fraction of
THP1 cells labeled with both 6E10 and CD68 (Figure 3F).
The fraction of dual labeled THP1 cells increased after
treatment with WT-Aβ42 and E22P-Aβ42 as the concentration
of these Aβ peptides increased, and SS-Aβ42 showed greater
changes. These data indicate that THP1 cells are able to
incorporate these Aβ peptides, but cells treated with SS-Aβ42
showed markedly increased dynamics.
Cytotoxicity of Aβ oligomers to various brain cells has been
evaluated experimentally, and much research has affirmed their
contribution to exacerbating AD pathology.6,8,41 As expected,
SS-Aβ42 displayed higher cytotoxicity on THP1 cells
compared to WT-Aβ42 and E22P-Aβ42. However, a question
remains as to what type of Aβ species causes this cytotoxicity
since Aβ species in a variety of sizes formed in 1% FBS/RPMI.
Previous findings suggest the difference in toxicity between
high (above 50 kDa) and low molecular weight Aβ
oligomers.41 High molecular weight Aβ oligomers are
implicated in inducing the formation of reactive oxygen
species and lipid peroxidation, resulting in impairment of
membrane integrity and subsequent LTP loss.42 As a limitation
of this study, we were not able to induce formation of Aβ
aggregates of defined sizes and structures. To further dissect
the pathophysiological role of Aβ species in different
structures, development of methods for induction and
purification of aggregates of constant size with potent
neurotoxicity are needed. Dimerization of SS-Aβ42 at the C-
terminal region might address this problem.43
Detection of an Epitope of SS-Aβ42 Antibody on
Human Brain Tissue. To study specific conformation of SS-
Aβ42, we produced a monoclonal antibody (TxCo-1) using
SS-Aβ42 as an immunogen and characterized its immunor-
eactivity by X-ray crystallography, enzyme immunoassay, and
immunohistochemistry.
After extensive screening, we obtained crystals diffracting to
2.5 Å resolution and its structure (Table 1). The SS-Aβ42
(15−30) peptide binds to the molecular surface of the TxCo-1
antibody (Figure 4). The residues 16−28 of SS-Aβ42 (15−30)
are clearly observed in electron densities. Several interactions
between SS-Aβ42 (15−30) and TxCo-1 are observed as
indicated in Figure 4B. In addition to such interatomic
interaction, there exist the π−π stacking interaction between
Phe19 in SS-Aβ42 (15−30) and Tyr103 of the H chain of
TxCo-1 and the CH/π interaction between Phe20 in SS-Aβ42
(15−30) and Pro100 of L chain of TxCo-1. The crystal
structure shows that TxCo-1 Fab recognizes the region
including positions 22 and 23 of the truncated form of SS-
Aβ42 (15−30), indicating that TxCo-1 is an antibody to the
toxic turn structure of Aβ (Figure 4A,B). Specificity of the
TxCo-1 antibody against SS-Aβ42 compared to WT-Aβ42 and
E22P-Aβ42 was assessed with enzyme immunoassay. The
TxCo-1 antibody showed high binding affinity against SS-Aβ42
(Figure 5A) but no significant immunoreactivity against WT-
Aβ42 and E22P-Aβ42. Next, we optimized the conditions for
immunohistochemistry with the TxCo-1 antibody on human
brain tissue. Immunoreactivity with TxCo-1 antibody was
detected in brain tissue from AD subjects upon pretreatment
with formic acid and antigen retrieval with EDTA (Figure 5B).
The TxCo-1 antibody-stained structures resembled neuritic
and diffuse plaques (arrow) and vascular Aβ (arrowhead). To
further confirm the specificity of the TxCo-1 antibody against
SS-Aβ42, preabsorption tests were performed. Preincubation
of the TxCo-1 antibody with its immunogen in 20-molar
excess for 1 h at 37 °C abolished the TxCo-1 staining of senile
plaques and blood vessels (Figure 5C). Furthermore, we
assessed cross-reactivity of the TxCo-1 antibody against WT-
Aβ42 and E22P-Aβ42. Preincubation of the TxCo-1 antibody



















completeness (%) 100.0 (100.0)
overall B factor from Wilson plot (Å2) 23.2
Refinement Statistics
resolution (Å) 2.5
no. of reflections 17192
Rwork/Rfree
c,d(%) 0.191/0.244
no. of atoms, Fab/peptide/others 3334/102/116
average B factor, Fab/peptide/others (Å2) 31.1/38.0/32.8
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bond length (Å) 0.0034
bond angle (deg) 1.277
Ramachandran plot
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aRmerge = Σ(|I − ⟨I⟩|)/Σ(I). bNumbers in parentheses refer to the
highest-resolution shell, 2.55−2.5 Å. cR = Σ||Fobs| − |Fcalc||/Σ|Fobs|.
dRwork is calculated from a set of reflections in which 5% of the total
reflections have been randomly omitted from the refinement and used
to calculate Rfree.
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Figure 4. Crystal structure of TxCo-1 Fab in complex with SS-Aβ42 (15−30). (A) Front (left) and top (right) views of the crystal structure of
TxCo-1 Fab in complex with the truncated form of SS-Aβ42 (15−30). Fab chains of H and L represented by ribbon models are indicated in green
and cyan, and SS-Aβ42 (15−30) is represented by stick models in magenta. Dashed line shows the disorder (134−136 of H chain). (B) SS-Aβ42
(15−30) binding site in TxCo-1/SS-Aβ42 (15−30) complex. The chain color is the same as presented in (A). The predicted interactions are drawn
with black dashed lines. The residue 15 of SS-Aβ42 (15−30) was truncated to alanine due to the poor electron density. Predicted interactions
between TxCo-1 Fab and SS-Aβ42 (15−30) are summarized in the box chart.
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Figure 5. Characterization of immunoreactivity of TxCo-1 antibody on human brain sample. (A) Assessment of the binding affinity of TxCo-1
antibody against WT-Aβ42 (red), E22P-Aβ42 (purple), SS (black)-Aβ42 peptides by enzyme immunoassay. The TxCo-1 antibody exhibited high
binding affinity to SS-Aβ42. (B) Representative images of postmortem human inferior parietal cortex of an age-matched non-neurological disease
control subject and an Alzheimer’s disease (AD) patient stained with TxCo-1 antibody. Senile plaques (arrow) and vascular amyloid (arrowhead)
were identified by TxCo-1 antibody. The images were taken with 20× objective lens. Scale bar, 100 μm. (C) Specificity of TxCo-1 antibody on
WT-Aβ42, E22P-Aβ42, SS-Aβ42. TxCo-1 antibody was incubated with or without Aβ peptides prior to incubation with brain tissues. Aβ peptides
were in 20 molar excess to TxCo-1 antibody. The images were taken under 10× objective lens. Scale bar, 200 μm. (D) Representative images of
postmortem human inferior parietal cortex sections of AD patients stained with TxCo-1, 6E10, and mOC64 antibodies. The images were taken
with 40× objective lens. Scale bar, 50 μm. (E) Colocalization analysis of TxCo-1/mOC64 and 6E10/mOC64 signals in 10 AD cases. Pearson
correlation coefficient (PCC) was calculated to reflect the degree of colocalization (0 = no colocalization, 1 = complete colocalization). (F)
Comparison of PCC between AD samples stained with TxCo-1/mOC64 and 6E10/mOC64. Data information: Significance was calculated using
Student’s t-test: ** P < 0.01.
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with WT-Aβ42 and E22P-Aβ42 in 20 molar excess did not
abolish TxCo-1 staining (Figure 5C). Lastly, we investigated
the similarity of Aβ structures identified by the TxCo-1
antibody on human brain tissue with Aβ plaques stained with
conventional Aβ antibodies: 6E10 and mOC64.44 Double
staining of brain tissues of AD patients with 6E10 and mOC64
showed extensive colocalization (Figure 5D, top panel). In
contrast, double staining of TxCo-1 and mOC64 exhibited
nonuniform patterns: extensive and moderate colocalization
(Figure 5D, middle and bottom panels). The degree of
colocalization, as Pearson correlation coefficient (PCC), of
TxCo-1/mOC64 and 6E10/mOC64 in 10 AD cases showed
that TxCo-1/mOC64 displayed a variety of PCC values
ranging from 0.4 to 0.9, whereas 6E10/mOC64 displayed
relatively uniform value (Figure 5E). The average of PCC
values in each case was compared between TxCo-1/mOC64
and 6E10/mOC64 stained groups and showed statistical
difference (Figure 5F). These data indicate that some Aβ
structures stained with TxCo-1 antibody are different from Aβ
plaques observed by using other Aβ antibodies.
Although genetic and experimental data suggest that excess
Aβ is a primary etiological event in the development of AD, the
fact that Aβ plaque burden does not correlate with clinical
staging of AD has been a major question in the field.2 As an
explanation, it has been suggested that Aβ deposits as plaques
could accumulate and sequester the soluble toxic Aβ
aggregate.45 When Aβ plaques lose their capacity as a buffer
for binding Aβ, the toxic Aβ species could leak out with
resulting damage in various areas in the brain. TxCo-1
antibody was developed using SS-Aβ42 as an immunogen,
and a set of experiments supported its specificity to the
immunogen.
In the crystal structure, the electron density of residues 16−
28 of SS-Aβ42 (15−30) is clearly observed whereas both ends
of SS-Aβ42 (15−30) must be disordered (Figure 4).
Therefore, TxCo-1 antibody might recognize the residues
16−28 of SS-Aβ42 (15−30). TxCo-1 antibody was also
specific to SS-Aβ42 and did not bind to WT-Aβ42 and E22P-
Aβ42. From these results, it is appropriate to consider that the
SS-Aβ42 would bind to TxCo-1 using the SS-Aβ42 (16−28)
region of SS-Aβ42 in the same manner as that of SS-Aβ42
(15−30). These results imply the presence of naturally
occurring Aβ with structural similarity to SS-Aβ42 in AD
patient brains. Interestingly, the TxCo-1 immunoreactive
pattern overlapped extensively but also had noticeable areas
of no overlap with immunoreactivity identified with conven-
tional Aβ antibodies. TxCo-1 immunoreactivity could suggest
localization of Aβ oligomers in AD brain, and the pattern is
consistent with soluble Aβ aggregates hypothesis. It will be of
interest to investigate the patterns of TxCo-1 immunoreactivity
with staging of AD pathology in a larger set of samples in a
future study. The potential application for using TxCo-1 for
measuring Aβ species in CSF and blood samples of AD
patients also deserves consideration for future studies.
■ CONCLUSION
Pathophysiology of Aβ oligomers has been an area of
significant research in AD. There remain unanswered questions
due to the technical difficulty in studying the tertiary structures
of Aβ oligomers with potent neurotoxicity. Furthermore,
characterization of Aβ oligomers in human brain, i.e., their
localization and dynamics in aging, has been quite challenging
due to the lack of a suitable antibody that detects either a basic
unit of toxic Aβ oligomers or toxic conformation of oligomers.
The aim of this study was to establish biological tools to study
“the conformation of toxic Aβ oligomers” using in vitro cell
culture and human brain sections.
The results indicate that SS-Aβ could be a useful tool to
model toxic Aβ oligomers. In addition, the antibody against
SS-Aβ (TxCo-1) detected putative Aβ oligomers in AD brain
with a different distribution compared with conventional Aβ
antibody, 6E10, suggesting that TxCo-1 might be a useful tool
for AD diagnosis in the early stage. However, several cautions
should be made for SS-Aβ and TxCo-1 since SS-Aβ with an
artificial disulfide bond is just a model of toxic Aβ in spite of
the lack of the proline substitution at position 22.
The nucleation of Aβ could be affected by other factors like
membrane, metal ions, and so on.9 Specific interaction
between GM1 and Aβ can result in the toxic Aβ species.10,46
Sciacca et al. proposed a common molecular mechanism of
membrane disruption by amylin, Aβ, and α-synuclein.47 The
role of apolipoproteins in the toxicity of Aβ oligomers has also
been reported.48 The effects on the toxic turn of Aβ at
positions 22 and 23 and the resultant toxic oligomers by these
factors remain to be investigated.
Although the mutation sites are concentrated in positions 22
and 23, there are other mutation sites (position 6, 7, or 21) in
the Aβ of familial AD patients than positions 22 and 23.
Therefore, this study does not exclude the existence of a toxic
conformer with a turn other than at positions 22 and 23. For
example, Sandberg’s study reported the neurotoxicity of an S−
S bridged Aβ at positions 21 and 30.18
In summary, this study demonstrated that the conformation-
restricted Aβ via intramolecular disulfide bond at positions 17
and 28, which forms stable Aβ oligomers, has strong
cytotoxicity in vitro. Furthermore, the TxCo-1 antibody,
designed to detect Aβ with this toxic conformation of Aβ
oligomers, identified this unique Aβ conformation in brain
tissue of AD patients. These reagents, SS-Aβ42 and TxCo-1
antibody, should aid in understanding the pathological role of
Aβ with toxic conformation in the development of AD.
■ MATERIALS AND METHODS
Human Postmortem Tissues. Autopsy-derived brain samples
were provided by the Fukushimura Brain Bank (Aichi, Japan). All
study subjects or their next of kin provided written informed consent
for the brain donation. This study complies with the Declaration of
Helsinki and was approved by the Ethics Committees of Shiga
University of Medical Science (reference number R2018-101), Kyoto
University (G0664-4), and Fukushimura Hospital (403). Formalin-
fixed paraffin-embedded sections (5 μm thick) of inferior parietal
cortex from ten patients with AD and three age-matched non-
neurological disease control subjects were used in this study. The
demographic details of subjects examined in this study are listed in
Table 2 [age at death, sex, postmortem interval (PMI), causes of
death and Braak stages for senile plaques/neurofibrillary tangle49 in
AD cases].
Antibodies. The primary antibodies used in this study were as
follows: Aβ antibody 6E10 (803001, Biolegend, San Diego, CA,
USA), Aβ antibody mOC64 (ab201060, Abcam, Cambridge, MA,
USA), anti-β III tubulin (ab18207, Abcam, Cambridge, MA, USA),
Iba1 (ab5076, Abcam, Cambridge, MA, USA), CD68 (ab213363,
Abcam, Cambridge, MA, USA), TxCo-1 (this study).
Synthesis and Preparation of Aβ Peptides. WT-Aβ42, E22P-
Aβ42, and SS-Aβ42 (hapten) were synthesized by previously reported
methods.29,39,50 The molecular weights were confirmed by ESI-
qTOF-MS, and their purity was determined by HPLC (>98%) as
reported previously.29,39,51 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP)
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(FUJIFILM, Osaka, Japan) was used in the preparation of Aβ
peptides for experiments. Synthesized Aβ peptides were dissolved in
HFIP to a final concentration of 1 mM. The peptides were incubated
for 60 min at 37 °C with mixing every 10 min, and HFIP was
evaporated using water pump vacuum for 30 min at room
temperature (RT). Dried peptides were dissolved in fresh dimethyl
sulfoxide (DMSO) (Nacalai Tesque, Kyoto, Japan) to a final
concentration of 400 μM. The peptides were stored at −80 °C
until use.
ThioflavinT (Th-T) Binding Assay. Aβ peptides prepared at 400
μM were diluted to make final concentrations of 4 μM in phosphate
buffered saline (PBS: 137 mM NaCl, 8.1 mM Na2HPO4, 2.68 mM
KCl, 1.47 mM KH2PO4, pH 7.4) or RPMI1640 tissue culture media
without phenol red (Nacalai Tesque, Kyoto, Japan) supplemented
with 1% fetal bovine serum (FBS) in protein LoBind tubes
(Eppendorf, Hamburg, Germany). For the control sample, DMSO
was added either to PBS or 1% FBS/RPMI1640 and made its final
concentration at 1%. For blank samples, PBS and 1% FBS/RPMI1640
were prepared. The samples were incubated at 37 °C for 24 h.
Thioflavin T (Th-T) (Anaspec, Fremont, CA, USA) was dissolved in
DMSO, adjusted to 10 mM. After 24 h incubation, 10 mM Th-T was
diluted in the samples to make a final concentration of 20 μM. An
amount of 100 μL of the samples was transferred to black 96-well
nonbinding surface microplates (Greiner, Kremsmünster, Austria).
The samples were incubated for 12 h at 24 °C. Th-T fluorescence was
measured at RT using an Infinite M200 plate reader (Tecan,
Man̈nedorf, Switzerland) through the top of the plate with excitation
filter of 430 nm and emission filter of 485 nm. The experiments were
conducted in triplicate. Fluorescence intensity changes were
calculated based on the fluorescence intensity of blank wells, as
previously described.52
Nondenaturing PAGE. To observe Aβ aggregates under
nondenaturing conditions (without detergents or reducing agents),
we used a method based on the Blue-native PAGE (BN-PAGE)
technique.53 Aβ peptides prepared at 400 μM were diluted to make
final concentrations of 0.25, 0.5, and 1.0 μM in either PBS or 1%
FBS/RPMI1640 in protein LoBind tubes. The samples were
incubated at 37 °C for 24 h. Then, 7.5 μL of each sample was
mixed with 2.5 μL of NativePAGE 4× sample buffer (ThermoFisher,
Waltham, MA, USA), and 2 μL of NativeMark unstained protein
standard (ThermoFisher, Waltham, MA, USA) was loaded onto a
NativePAGE 4−16%, Bis-Tris gel (ThermoFisher, Waltham, MA,
USA) and electrophoresed for 25 min at 250 V using the dark-blue
running buffer of the manufacturer. At that time, proteins had
migrated through a third of the gel length, and then buffer was
exchanged for light-blue running buffer. The gel was further
electrophoresed at 150 V for 60 min, at 10 V for 70 min, then at
150 V until proteins reached about 1 cm above the bottom of the gel.
After electrophoresis, proteins were transferred to PVDF membrane
(Immobilon-P, Merck Millipore, Burlington, MA, USA) using a
semidry transfer apparatus.54 Membranes were blocked in 5%
skimmed milk dissolved in Tris-buffered saline with 0.1% Tween 20
(TBST: 20 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.1% Tween 20)
for 1 h at RT. Membranes were incubated with 6E10 antibody at 0.5
μg/mL in blocking buffer for 16 h at 4 °C. On the following day,
membranes were washed for 10 min × 3 with TBST and incubated 1
h in HRP-labeled anti-mouse immunoglobulin G (IgG) (Thermo-
Fisher, Waltham, MA, USA) at 1:5000 in 2% skimmed milk dissolved
in TBST. Membranes were washed for 10 min × 3 with TBST and
exposed to Chemi-Lumi One chemiluminescent substrate (Nacalai
Tesque, Kyoto, Japan). The chemiluminescent signal was recorded
with the Fusion Solo-S imager (Vilber, Marne-La-Valleé, France).
Photoinduced Cross-Linking of Unmodified Proteins
(PICUP). Cross-linking of Aβ followed a published protocol.30
Synthesized Aβ peptides were dissolved in HFIP to a final
concentration of 1 mM. The peptides were incubated for 60 min at
37 °C with mixing every 10 min, and HFIP was evaporated using a
water pump vacuum for 30 min at room temperature. Dried peptides
were dissolved at a concentration of 50 μM in 10% (v/v) 60 mM
NaOH and 90% (v/v) 10 mM phosphate buffer, pH 7.65. The
samples were used immediately after being dissolved in the buffer or
incubated at 37 °C for 5 min prior to the next step. Then, Aβ peptides
were mixed with ammonium persulfate (Nacalai Tesque, Kyoto,
Japan) and tris(2,2′-bipyridyl)dichlororuthenium(II) (TCI, Tokyo,
Japan) in a molar ratio of 1:40:2. The mixture was irradiated for 0.25 s
with 25000 lm LED flashlight, and the reaction was quenched with
reducing tricine sample buffer [5% (v/v) β-mercaptoethanol, 3% (wt/
vol) SDS, 10% glycerol (w/v), 0.05% Coomassie blue G-250 in 37.5
mM Tris/HCl (pH 7.0)]. Samples were separated by using 10−20%
Tris-tricine gradient gel (ThermoFisher, Waltham, MA, USA). After
SDS/PAGE, the bands were visualized by silver staining (silver stain
II kit Wako, Osaka, Japan).
Morphological Analysis of Aβ Fibril in Confocal Microscope.
Round cover glasses (C013001, Matsunami, Osaka, Japan) were
placed in a 24-well cell culture plate (IWAKI, Shizuoka, Japan).
Collagen I (Corning, Glendale, AZ, USA) (10 μg/mL in 0.02 M
acetic acid) was added to the wells (500 μL/well) with the cover
glasses and incubated at RT for 1 h. Treated wells were washed twice
with PBS. Aβ peptides prepared at 400 μM were diluted to make final
concentrations of 1.0 μM in either PBS or 1% FBS/RPMI1640 and
transferred to the wells with the cover glasses. PBS or 1% FBS/
RPMI1640 with Aβ peptides were incubated at 37 °C for 24 h. The
cover glasses were transferred to a new 24-well plate and fixed with
50% acetone/50% EtOH for 15 min on ice. Once dried, the cover
glasses were washed with PBS for 5 min × 2, blocked with 3% donkey
serum in PBS containing 0.1% Tween 20 for 1 h at RT, and then
incubated with 6E10 (1 μg/mL) in blocking buffer for 16 h at 4 °C.
On the following day, the cover glasses were washed in PBS with 0.1%
Tween 20 for 5 min × 3, then incubated with Alexa Fluor 488 anti-
mouse IgG secondary antibody in PBS with 0.1% Tween 20 for 1 h at
RT. The cover glasses were washed in PBS for 5 min × 3 and
mounted on microscope slide using antifade mounting media (Vector
Laboratories, Burlingame, CA, USA). Immunofluorescent images
were taken on a Leica SP8 confocal microscope (Leitz, Wetzlar,
Germany)
Morphological Analysis of Aβ Fibril by Atomic Force
Microscopy (AFM). AFM images were obtained on a high-speed
AFM (Nano Live Vision, RIBM, Tsukuba, Japan) using a silicon
nitride cantilever (Olympus BL-AC10DS-A2). SS-Aβ42 peptides
prepared at 400 μM were diluted to make a final concentration of 1.0
μM in PBS and incubated at 37 °C for 24 h. The samples (2 μL) at 0
and 24 h incubation were absorbed on a freshly cleaved mica plate for
5 min at RT and then washed with the buffer solution. Scanning was
performed in the same buffer solution using a tapping mode.
THP-1 Cell Culturing and Differentiation. THP-1 monocytes
(TIB-202) obtained from the American Type Culture Collection
(Manassas, VA, USA) were cultured in suspension using RPMI1640
media supplemented with 10% FBS. Differentiation of cells was
conducted by treatment with 100 nM phorbol myristate acetate
(PMA) (Sigma-Aldrich, St. Louis, MO, USA) for 48 h in 5% FBS/
RPMI1640. After 48 h, culture media with PMA were exchanged with
Table 2. Summary of Sample Demography
case no. age sex PMI (h) Braak stage NP diagnosis
1 84 F 3 C/5 AD
2 92 F 2 C/6 AD
3 92 F 5 C/5 AD
4 75 F 4.5 C/6 AD
5 88 F 1 C/6 AD
6 90 M 15 C/6 AD
7 83 F 3 C/6 AD
8 86 M 10.5 C/4 AD
9 98 F 2.5 C/5 AD
10 86 F 17 C/4 AD
11 86 M 16.5 0/1 non-AD
12 90 F 5.5 0/2 non-AD
13 82 M 16.5 0/1 non-AD
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fresh 5% FBS/RPMI1640 for 24 h. For differentiation in 96-well plate
(IWAKI, Shizuoka, Japan), 25 000 cells were seeded in a well. For
differentiation in 24-well plates on round cover glasses 100 000 cells
were seeded in each well.
MTT Assay. Cell viability was assessed using MTT cell count kit
(Nacalai Tesque, Kyoto, Japan) in accordance with the manufac-
turer’s protocol. THP-1 cells were differentiated in 96-well plate as
described above. Aβ peptides prepared at 400 μM were diluted to
make final concentration of 25, 50, 100, 250, 500, and 1000 nM in
RPMI1640 supplemented with 1% FBS. For the control sample,
DMSO was mixed in 1% FBS/RPMI1640 and made its final
concentration at 0.25%. 100 μL of prepared media containing Aβ
peptides at various concentrations was added to differentiated THP-1
cells, and the cells were incubated at 37 °C for 24 h. 10 μL of MTT
solution was added to each well, followed by 3 h incubation at 37 °C.
100 μL of MTT solubilization solution was applied on each well and
mixed by pipetting. Absorbance at 570 nm was measured using an
Infinite M200 plate reader. Cell viability was calculated based on the
absorbance obtained by THP-1 cells incubated in 0.25% DMSO/1%
FBS/RPMI1640 media as 100%. The experiments were conducted in
triplicate, and the values were averaged.
Immunofluorescence Microscopy on THP-1 Cells. THP-1
cells were differentiated in 24-well plate as described above. Aβ
peptides prepared at 400 μM were diluted to make final concentration
of 0.25, 0.5, and 1.0 μM in 1% FBS/RPMI1640. 500 μL of prepared
media containing Aβ peptides at various concentrations was applied
on differentiated THP-1 cells, and the cells were incubated at 37 °C
for 24 h. For experiments involving bafilomcyin A1 treatment,40 10
mM bafilomycin A1, dissolved in DMSO, was diluted to make final
concentration of 50 μM in 1% FBS/RPMI1640. Then, Aβ peptides
were diluted to make final concentrations of 0.25, 0.5, and 1.0 μM in
50 μM bafilomycin A1/1% FBS/RPMI1640. The cover glasses with
differentiated THP1 cells were transferred to a new 24-well plate and
fixed with 50% acetone/50% EtOH for 15 min on ice. Once dried, the
cells were washed with PBS for 5 min × 2, blocked with 3% donkey
serum in PBS containing 0.1% Tween 20 for 1 h at RT. Then, the
cells were incubated with antibodies 6E10 (1 μg/mL), CD68 (1.2 μg/
mL), and Iba1 (1 μg/mL) in blocking buffer for 16 h at 4 °C. On the
following day, the cells were washed in PBS with 0.1% Tween 20 for 5
min × 3. The cells were incubated with Alexa Fluor 488 anti-mouse
IgG, 555 anti-rabbit IgG, and 647 anti-goat IgG secondary antibodies
in PBS with 0.1% Tween 20 for 1 h at RT. The cells were washed in
PBS for 5 min × 3 and mounted on microscope slide using antifade
mounting media. Immunofluorescent images were taken on a Leica
SP8 confocal microscope.
Imaging and Data Analysis. Two montage images were
captured for Aβ colocalization analysis on THP-1 cells. Each montage
consisted of a 3 × 3 panel of images captured with a 40× objective
lens encompassing an area of 0.762 mm2. The pattern of 6E10 signal
localized in THP1 cells was categorized into three groups: puncta,
aggregate, and diffuse. The puncta and aggregate patterns were
defined by 6E10-immunofluorescent spot less of 1 μm and over 3 μm,
respectively. The diffuse pattern is defined by a 6E10-immuno-
fluorescent diffuse signal throughout the cell body. THP-1 cells
identified by Iba1 signal in the measured field were counted to
calculate the fraction of the cells with 6E10 signal in each category.
For the Aβ colocalization analysis on THP-1 cells treated with
bafilomycin A1, the CD68 signal was used to calculate the fraction of
the cells with 6E10 signal. The calculated values from the two
montage images in each sample were averaged for the final analysis.
Development of TxCo-1 (10A1) Antibody. S−S bridged L17C,
K28C-Aβ42 as an immunogen for the toxic conformation-restricted
analog of Aβ42 was synthesized by a previously described method.29
Mice (BDF-1, Charles River, Japan) were immunized weekly for a
month with the immunogen (50 μg/mouse) mixed with complete
Freund’s adjuvant followed by booster injections with the antigen in
incomplete Freund’s adjuvant three times. A 96-well Maxisorp plate
(Nunc, Roskilde, Denmark) coated with the immunogen (50 μg/mL)
was incubated with the obtained clones for 1 h at RT, followed by
treatment with a horseradish peroxidase-coupled anti-mouse IgG
antibody [Immuno-Biological Laboratories (IBL), Gunma, Japan],
and quantified using 3,3′,5,5′-tetramethylbenzidine (Kementec,
Taastrup, Denmark) or o-phenylenediamine dihydrochloride sub-
strate (Sigma-Aldrich, St. Louis, MO, USA). A total of 45 clones were
obtained, identified for their ability to bind the immunogen, and then
were subcloned to obtain seven clones. The screening was repeated to
exclude weak or false positives. They were further screened for the
inability to bind WT-Aβ42, E22P-Aβ42, and WT-Aβ40. As a result,
clone 10A1 was selected, whose isotype was IgG1. Mice used for the
development of antibodies were maintained according to the
protocols approved by the Animal Care Committee of IBL Co., Ltd.
Crystallographic Study of the TxCo-1 Antibody. Fab
fragment of the TxCo-1 antibody was prepared from papain digests
and purified by gel filtration using Superdex 200 column (GE
healthcare, Chicago, IL, USA) with PBS buffer. The purified Fab
proteins were dialyzed against PBS, after absorption of Fc fragments
with Protein A Sepharose, and concentrated to approximately 1 mg/
mL to which a truncated hapten peptide [S−S bridged L17C, K28C-
Aβ (15−30)] was added to adjust the molar ratio of the Fab and the
peptide to 1:3. The mixture was further concentrated up to
approximately 8 mg/mL using the Amicon centrifugation kit (Amicon
Ultra 10K, 14 000g, 293 K, 7 min). The truncated hapten peptide was
synthesized by the method reported previously,29 and its molecular
weight was confirmed by ESI-qTOF-MS. Crystallization condition
was screened with the sitting-drop vapor diffusion method using
commercial crystallization kits at 293 K. The crystals of TxCo-1-
peptide complex were obtained from a 1:1 mixture of the protein and
precipitant solution (18% (w/v) polyethylene glycol monomethyl
ether 5000, and 0.2 M magnesium formate in 0.1 M sodium acetate
buffer (pH 4.0)). The crystals belong to the space group C2 with cell
dimensions of a = 185.0 Å, b = 40.5 Å, c = 69.4 Å, and β = 97.2°.
Before data collection, crystals were soaked for 15−20 s in precipitant
solutions containing 25% ethylene glycol as cryogenic solutions and
then frozen in liquid N2. X-ray diffraction data were collected under a
nitrogen gas stream at 100 K using synchrotron radiation with an
EIGER X4M detector on the BL1A beamline at Photon Factory. The
diffraction data were processed and scaled with the XDS package55
and Aimless program56 from the CCP4 suite.57 The structure of the
TxCo-1-Fab complex was solved at 2.5 Å resolution by the molecular
replacement method using the program Molrep58 from the CCP4
suite,57 with the coordinates of anti-E22P-Aβ antibody 24B359 as a
search model (unpublished data). The models were manually
constructed using the program Coot,60 and structure refinement
was performed with the program REFMAC.57,61 The final model of
TxCo-1-peptide consists of L-chain, H-chain, Aβ (residue numbers
15−28), 3 ethylene glycols, 2 polyethylene glycols, and 91 water
molecules. The quality of the model was checked using the
MolProbity62 server at http://molprobity.biochem.duke.edu/. The
data collection and refinement statistics are summarized in Table 1.
Figures of crystal structure were prepared using the program PyMOL
(The PyMOL Molecular Graphics System, version 2.3, Schrödinger,
LLC.) unless otherwise stated.
PDB Reference. The atomic coordinates and structure factors of
TxCo-1-peptide complex have been deposited in the Worldwide
Protein Data Bank (wwPDB), with the accession code of 7E6P.
Enzyme Immunoassay (EIA). In a 96-well Maxisorp plate (Nunc,
Roskilde, Denmark), each Aβ peptide (500 pmol/well) dissolved in
50 mM sodium carbonate was incubated for 2 h at RT, followed by
blocking with 5% bovine serum albumin at 4 °C overnight, as
previously described.63 Briefly, after incubation of TxCo-1 antibody
with each peptide for 1 h at RT, the plate was treated with a
horseradish peroxidase-coupled anti-mouse IgG antibody (IBL,
Gunma, Japan) and quantified using o-phenylenediamine dihydro-
chloride substrate (Sigma-Aldrich, St. Louis, MO, USA) before
measurements at 492 nm with a microplate reader (MultiScan JX;
Thermo Scientific).
Immunohistochemistry with Fluorescent Probes on Human
Brain. Immunohistochemistry with fluorescent probes and screening
of tissue quality of cerebellum with β-tubulin immunohistochemistry
were performed as previously described.64 High-quality samples were
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selected for this study. Tissue sections were deparaffinized in xylene
and rehydrated in 100% EtOH for 5 min × 3, 90% EtOH for 5 min,
and 70% EtOH for 5 min. After washing with tap water, samples were
incubated with 70% formic acid for 12 min at RT prior to antigen
retrieval. Antigen retrieval was performed in 1 mM EDTA (pH 8.0)
by boiling for 10 min. For cerebellum, antigen retrieval was performed
in citrate buffer (pH 6.0) (Abcam, Cambridge, MA, USA) by boiling
for 10 min. Samples were blocked with 5% donkey serum in PBS
containing 0.2% Triton X-100 for 1 h at RT. Then, samples were
incubated with TxCo-1 (1 μg/mL)/mOC64 (1 μg/mL) or 6E10 (2
μg/mL)/mOC64 (1 μg/mL) in blocking buffer for 16 h at 4 °C. On
the following day, samples were washed in PBS with 0.3% Triton X-
100 for 5 min × 3. Then, samples were incubated with Alexa Fluor
488 anti-mouse IgG and 555 anti-rabbit IgG secondary antibodies in
PBS with 0.5% Tween 20 for 1 h at RT. Samples were washed in PBS
once for 5 min. For quenching lipofuscin autofluorescence, TrueBlack
lipofuscin autofluorescence quencher (Biotium, Fremont, CA, USA)
diluted 1/40 in 70% EtOH was applied to samples and incubated for
50 s at RT. Samples were washed with PBS for 5 min × 3 and
coverslipped using antifade mounting media. Immunofluorescent
images were taken on a Leica SP8 confocal microscope.
Immunohistochemistry with 3,3′-Diaminobenzidine (DAB)
Development. Sections were deparaffinized in xylene for 5 min × 3
and rehydrated in 100%, 90%, and 70% EtOH. After washing with tap
water, the tissues were incubated in 0.3% hydrogen peroxidase
solution for 15 min at RT followed by 70% formic acid for 12 min at
RT prior to antigen retrieval. After washing with tap water, antigen
retrieval was performed in 1 mM EDTA (pH 8.0) by boiling for 10
min. Samples were blocked with 5% donkey serum in PBS containing
0.2% Triton X-100 for 1 h at RT. Samples were incubated with TxCo-
1 antibody at 1 μg/mL in blocking buffer for 16 h at 4 °C. On the
following day, samples were washed in PBS with 0.3% Triton-X100
for 5 min × 3, then biotinylated anti-mouse IgG (H+L) (Vector
Laboratories, Burlingame, CA, USA) in PBS with 0.5% Tween 20 was
applied and incubated for 1 h at RT. Samples were washed in PBS for
5 min x 3, and VECTASTAIN ABC-HRP Kit, Peroxidase (Vector
Laboratories, Burlingame, CA, USA) was applied and incubated for 1
h at RT. Samples were washed in PBS for 5 min × 3, and DAB
(Vector Laboratories, Burlingame, CA, USA) solution was applied
and incubated for 2 min at RT. Counterstaining was performed with
hematoxylin for 10 s. After dehydration and incubation in xylene,
samples were coverslipped. Images were taken on Olympus BX50
light microscope.
Colocalization Analysis of mOC64 Antibody with 6E10 and
TxCo-1 Antibodies. Brain tissues from 10 different AD cases were
immunostained with TxCo-1/mOC64 or 6E10/mOC64 mixtures as
described above. Five montage images were captured using a Leica
SP8 confocal microscope for each case. The setting of the montages
consisted of a 3 × 3 panel of images taken on ×40 objective lens
encompassing an area of 0.762 mm2. To quantify colocalization of
TxCo-1 immunoreactivity (IR) with mOC64 IR and 6E10 IR with
mOC64 IR, the images were analyzed using EzColocalization plugin
for ImageJ.65 The top 10% of pixels above threshold (FT 10%) were
chosen for the analysis. The Pearson correlation coefficient was
calculated to reflect the degree of colocalization (0 = no
colocalization, 1 = complete colocalization).
Statistical Analysis. The data are presented as the mean ± SD.
Statistical analyses were performed with GraphPad Prism (version
7.0). One-way analysis of variance with post-hoc Tukey’s test for
multiple comparisons was conducted for the data analysis in Figures
1A, 2A, and 3A,D. Two-way analysis of variance with post-hoc
Tukey’s test for multiple comparisons was conducted for the data
analysis in Figure 3C,F. The Student’s t test was conducted to the
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